PMID- 22134384
OWN - NLM
STAT- MEDLINE
DCOM- 20120403
LR  - 20220316
IS  - 1473-5598 (Electronic)
IS  - 0263-6352 (Linking)
VI  - 30
IP  - 1
DP  - 2012 Jan
TI  - Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: 
      a systematic review and meta-analysis.
PG  - 3-16
LID - 10.1097/HJH.0b013e32834d249a [doi]
AB  - BACKGROUND: Hypertension is a major cause of cardiovascular remodeling. In the 
      cardiovascular system, the remodeling of the extracellular matrix is controlled 
      by the matrix metalloproteinases (MMPs) and the tissue inhibitors of MMPs 
      (TIMPs). The aim of this meta-analysis is to elucidate the behavior of plasma MMP 
      and TIMP levels in hypertension and their relationship to cardiovascular 
      remodeling. METHODS: MEDLINE and EMBASE databases were searched up to July 2011. 
      Studies were considered eligible if they provided values of plasma MMPs and TIMPs 
      in hypertensive patients. Given the high variability of the plasma biomarker 
      values among studies, the standardized mean difference (SMD) was calculated. 
      RESULTS: Ten studies provided plasma MMP-9; the SMD between 778 hypertensive 
      patients and 669 controls was 1.95 units (P < 0.05). Thirteen studies provided 
      plasma TIMP-1; the SMD between 851 hypertensive patients and 646 normotensive 
      individuals was 1.92 units (P < 0.01). Three studies investigated whether plasma 
      TIMP-1 predicted left ventricular (LV) remodeling; the SMD between 92 
      hypertensive patients with and 88 hypertensive patients without LV hypertrophy 
      was 5.81 units (P < 0.05). As for diastolic heart failure (HF), five studies 
      provided data for plasma MMP-2; the SMD between 321 hypertensive patients with 
      and 334 hypertensive patients without HF was 2.36 units (P < 0.01). The 
      heterogeneity among studies was high. CONCLUSIONS: These results suggest that 
      MMP-2, MMP-9 and TIMP-1 may have a role as biomarkers of cardiovascular 
      remodeling in hypertension. If these results are confirmed in prospective 
      clinical studies, they could provide new tools to stratify cardiovascular risk in 
      hypertensive patients.
FAU - Marchesi, Chiara
AU  - Marchesi C
AD  - Department of Clinical Medicine, University of Insubria, Varese, Italy. 
      chiara.mrc@gmail.com
FAU - Dentali, Francesco
AU  - Dentali F
FAU - Nicolini, Eleonora
AU  - Nicolini E
FAU - Maresca, Andrea M
AU  - Maresca AM
FAU - Tayebjee, Mazahir H
AU  - Tayebjee MH
FAU - Franz, Marcus
AU  - Franz M
FAU - Guasti, Luigina
AU  - Guasti L
FAU - Venco, Achille
AU  - Venco A
FAU - Schiffrin, Ernesto L
AU  - Schiffrin EL
FAU - Lip, Gregory Y H
AU  - Lip GY
FAU - Grandi, Anna M
AU  - Grandi AM
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
PL  - Netherlands
TA  - J Hypertens
JT  - Journal of hypertension
JID - 8306882
RN  - 0 (Protease Inhibitors)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
CIN - J Hypertens. 2012 Jan;30(1):34-7. PMID: 22157583
MH  - Humans
MH  - Hypertension/*blood
MH  - Matrix Metalloproteinases/*blood
MH  - Protease Inhibitors/*blood
EDAT- 2011/12/03 06:00
MHDA- 2012/04/04 06:00
CRDT- 2011/12/03 06:00
PHST- 2011/12/03 06:00 [entrez]
PHST- 2011/12/03 06:00 [pubmed]
PHST- 2012/04/04 06:00 [medline]
AID - 10.1097/HJH.0b013e32834d249a [doi]
PST - ppublish
SO  - J Hypertens. 2012 Jan;30(1):3-16. doi: 10.1097/HJH.0b013e32834d249a.